Research

Recent Publications

“Impact of cold ischemia time on outcomes of liver transplantation: A single center experience.”  Sibulesky L, Li M, Hansen R, Dick A.S., Monteonvo MI, Rayhill SC, Bakthavatsalam R, Reyes JD. Ann of Transplant. 2016 Mar 8;21:145-51.

“Donor Age still Matters in Liver Transplantation: Results from the UNOS-SRTR Database.”
Montenovo MI, Hansen R, Dick A, Reyes JD.  Exp Clin Transplant. 2016. In press

“Superior patient and graft survival in adult liver transplantation with rabbit anti-thymocyte globulin induction: Experience with 595 patients.” Montenovo MI, Jalikis FG, Li M, Yeh M, Dick A, Hansen R, Reyes JD.  Exp Clin Transplant. 2016. Doi: 10.6002/ect.2015.0350.

“Interventional and Surgical Techniques in Solid Organ Transplantation.”
Ingraham CR, Montenovo MI.  Radiol Clin North Am. 2016; 54:267-280.

“Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit.”  Su F, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Gastroenterology. 2016 Feb;150(2):441-53.e6; quiz e16. doi: 10.1053/j.gastro.2015.10.043. Epub 2015 Oct 30.  PMID:  26522262

“RIO kinase 3 over expression promotes hepatocellular carcinoma invasion through induction of epithelial-mesenchymal transition and a potential link to WNT/beta-catenin pathway activation.” Das T, Hassan S, Feng Q, Gretch D, Reyes JD and Perkins JD. Journal of Liver: disease and transplantation, Sep 2014.

“Is MELD Score a Significant Predictor of Post-Transplant Mortality? An Old Issue with Simple Answer.” Rahnemai-Azar A, Perkins J, Montenovo M, Rayhill S, Bakthavatsalam R, Leca N, Blosser C, Di Castro I, Bhattacharya R, Reyes J, Sibulesky L. Am J Transplant. 2016, 16 (suppl 3), 557

Research Highlights

Grants

Stephen C. Rayhill, MD— “A 24-month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs. mycophenolate with standard calicnerurin inhibitor in de novo renal transplantation—Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM).” Novartis Pharmaceutical Corporation. Co-investigator IRB #47855  Trial Protocol CRAD001A244. 8/6/14-12/31/2018, $226,674

 “A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation   After Brain Death Older Donor Kidney Transplant (ReGIFT).” Quark Pharmaceuticals, Inc. 2016- present

James D. Perkins, MD and Jorge D. Reyes, MD—  “Genomic Analysis of Hepatoblastoma in Children: Pilot study to identify specific genes indicating recurrence after treatment for hepatoblastoma for future longitudinal studies.” Gerber Foundation. 12/2/2013-present  $144,839

Clinical Outcomes and Quality Performance Measures

– Clinical Outcomes Research in Transplantation – Quality Performance Measures in Surgery


perkins_james_tsdJames D. Perkins, MD
Professor Clinical outcomes research examines specific illnesses and therapies and evaluates whether current practices are truly effective. Questions are asked about such factors as medication dosages, operative techniques, information management, and infection control. Based on the results of these studies, protocols may be adjusted to give improved results. Improved results in the field of transplantation might take the form of higher patient survival rates, lower rejection rates concomitant with low infection rates, more effective use of immuosuppressive therapy, or shorter hospital stay. Complete Research Report >>

Translational Studies and Clinical Outcomes Investigations in Transplantation

Translational Studies and Clinical Outcomes Investigations in Transplantation  

Jorge D. Reyes, MD Professor and Chief New immunosuppressive drugs improve the short-term survival of organ transplant recipients. However, long-term survival remains comparatively poor. This is likely due to the fact that immunosuppressive strategies are not tolerogenic. Transplant tolerance is likely to arise not from improved immunosuppressive regimens, but from improved understanding of the normal mechanisms that generate and maintain self-tolerance, and the ability to manipulate these mechanisms for the prevention and treatment of transplant rejection. Complete Research Report >>